Conditions: Migraine
Keywords: Lacosamide migraine prophylaxis Vimpat
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 218
Healthy volunteers: no

Brief summary:
The purpose of this study is to see how safe and effective Lacosamide (LCM) is when taken by mouth, twice a day for up to 18 weeks to prevent migraines.

Detailed description:
This study is for subjects who have been diagnosed with migraine for at least one year and who are currently taking an effective abortive medication(s).

Arms:
arm 1: Placebo arm 2: 100mg lacosamide arm 3: 300mg lacosamide

Interventions: intervention 1: Lacosamide intervention 2: Placebo intervention 3: Lacosamide
Intervention descriptions: intervention 1: Lacosamide 100mg immediate-release film-coated tablet (white,oval) oral administration twice daily 12 hours apart intervention 2: Immediate-release film coated tablet (white, oval), oral administration twice daily 12 hours apart intervention 3: Lacosamide 300mg, immediate-release film coated tablet (white,oval), oral administration twice daily 12 hours apart.

Protocol document: